Search

Filters
Clear All
  • 1
  • 1
  • 3

Phase

  • 1
  • 4
  • 4
  • 2

Found 5 Growth trials

A listing of Growth medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

MRI Placental Changes in Prenatally Diagnosed Intrauterine Growth Restriction

B
Brandon Brown, MD
18-100 years
Female
Observational
The purpose of this study is to better understand intrauterine growth restriction (IUGR), which is a common diagnosis during pregnancy.

Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT (T4G RCT)

R
R. Mark Payne, MD
All genders
Phase 3
Interventional
This is a Phase III randomized controlled trial of a passive ROM exercise program that will be performed in infants with HLHS and other single right ventricle anomalies following the Norwood procedure at PHN and Auxiliary Centers.

Understanding hair follicle structure & pigmentation genetics: expression/methylation differences found in hair growth location.

S
Susan Walsh
18-100 years
Male
The purpose of this study is to research on the genes that cause different hair colors in an individual using the genetic information extracted from the hair samples the study participants provide.

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

S
Shadia Jalal, MD
18-100 years
All genders
This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.

A Phase 1 Study Of Ramucirumab a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors Including CNS Tumors

J
James Croop, MD, PhD
1-21 years
All genders
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.